Publications by authors named "Ippokratis Korantzis"
What Is This Summary About?: This is a summary of a phase 2 clinical study called DeLLphi-301. The study looked at how effective and safe a medicine called tarlatamab was in participants with small cell lung cancer (SCLC). Participants previously received at least two other treatments for their SCLC.
View Article and Find Full Text PDFArticle Synopsis
- Tarlatamab is a bispecific T-cell engager immunotherapy that showed promising results in a phase 1 trial for patients with previously treated small-cell lung cancer.
- In a phase 2 trial involving 220 patients, tarlatamab was administered intravenously every 2 weeks at doses of 10 mg or 100 mg, with an objective response rate of 40% and 32% respectively.
- The study found that common side effects included cytokine-release syndrome, decreased appetite, and fever, with overall survival rates at 9 months being 68% for the 10-mg group and 66% for the 100-mg group.
Article Synopsis
- The study aimed to gather real-world data on the EGFR mutational profile and treatment strategies for advanced non-small-cell lung cancer (NSCLC) patients after first/second-generation EGFR-TKI treatment.
- Ninety-six patients were enrolled in Greece, with re-biopsies conducted for some who were negative for the T790M mutation.
- Results showed that 21.9% of patients were T790M-positive, and those receiving third-generation EGFR-TKIs had better outcomes, highlighting the importance of mutational status and treatment choices in improving response rates and progression-free survival.
Article Synopsis
- A European registry was established for patients with advanced EGFR exon 20-mutant non-small cell lung cancer (NSCLC) diagnosed between January 2019 and December 2021, specifically excluding those enrolled in clinical trials.* -
- The final analysis included data from 175 patients across nine countries, revealing a median age of 64 years, predominantly affecting women (56.3%) and mostly comprising adenocarcinoma cases (95.4%) with frequent bone (47.4%) and brain (32.0%) metastases.* -
- Treatment patterns varied significantly: chemotherapy and chemotherapy-immunotherapy combinations were used in 33.8% and 18.2% of cases respectively, with disease control rates of
Article Synopsis
- * Researchers analyzed genetic data from 100 Greek men diagnosed with MBC between 1995-2015, examining BRCA1, BRCA2, and 43 other cancer-related genes.
- * They found pathogenic variants in 13 patients, confirming BRCA2 as the primary genetic risk factor for MBC, while other genes had minimal involvement, complicating the assessment of their collective impact.
Background/aim: Low expression of HER2 has defined a new "HER2-low" subgroup of breast cancer with distinct clinicopathological characteristics and both prognostic and predictive implications. The impact of low HER2 expression in metastatic hormone receptor-positive HER2-negative breast cancer treated with first-line CDK4/6 inhibitors has not been studied. Using real-world patient data, we aimed to identify prognostic differences in this patient population according to HER2 expression with immunohistochemistry.
View Article and Find Full Text PDFBackground: During the last decade, significant improvement was made in systemic therapy of pancreatic adenocarcinoma (PAC). The impact of this progress in everyday clinical practice has not been fully described yet. The aim of the study was to investigate the pattern followed by Greek Medical Oncologists regarding the treatment of patients with PAC.
View Article and Find Full Text PDFObjective: Sorafenib is the standard of care for patients with advanced hepatocellular carcinoma (HCC), but data on its use in the elderly are inconclusive.
Methods: All consecutive HCC patients who were treated in our institution with sorafenib since its licensing were included in the analysis. Patients were divided into two groups: (A) up to 75 and (B) older than 75 years old.
Summary: Improved diagnostic methods and medical therapies are necessary for early detection and treatment and an improved prognosis. It is thus vital to both examine and evaluate the role of the various existing proteins as biomarkers in carcinogenesis and to assess the contribution of these proteins in anti-cancer activity, for consideration in therapeutic strategies. It is essential to both examine and evaluate the role of the various existing proteins as biomarkers in carcinogenesis and to assess the contribution of these proteins in anti-cancer activity, for consideration in therapeutic strategies.
View Article and Find Full Text PDFBackground: Metronomic chemotherapy targets the inhibition of tumor growth primarily through antiangiogenic mechanisms. The aim of the present study was to investigate the antiangiogenic properties of weekly metronomic docetaxel administration in patients with metastatic breast cancer.
Patients And Methods: In total, 157 patients with metastatic breast cancer received docetaxel at 35 mg/m(2) on a weekly basis as first-line treatment.
Background: BRCA1 (B), ERCC1 (E), RRM1 (R) and TYMS (T) mRNA expression has been extensively studied with respect to NSCLC patient outcome upon various chemotherapy agents. However, these markers have not been introduced into clinical practice yet. One of the reasons seems to be lack of a standard approach for the classification of the reported high/low mRNA expression.
View Article and Find Full Text PDFIt is well known that low-dose metronomic chemotherapy has antiangiogenic activity. The aim of the present trial was to investigate the antiangiogenic properties of weekly docetaxel in patients with metastatic breast cancer. In total, 157 metastatic breast cancer patients received 35 mg/m2 docetaxel weekly as a recommended treatment.
View Article and Find Full Text PDFA randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study.
BMC Med
January 2011
Background: Colon cancer is a public health problem worldwide. Adjuvant chemotherapy after surgical resection for stage III colon cancer has been shown to improve both progression-free and overall survival, and is currently recommended as standard therapy. However, its value for patients with stage II disease remains controversial.
View Article and Find Full Text PDFArticle Synopsis
- Metastatic ovarian involvement from malignant melanoma is rare, often indicating advanced disease and poor outcomes, complicating diagnosis due to its similarity to primary ovarian cancer.
- A case study highlights a premenopausal woman with late-stage melanoma that spread to her abdomen and ovaries, where ascitic fluid analysis provided an accurate diagnosis and helped avoid unnecessary surgeries.
- Effective diagnosis using less invasive methods is essential to manage the prognosis and provide appropriate care, reserving surgery for select cases where complete removal of limited metastasis is possible.